Item 11.2 Framework of engagement with non-State actors Delivered by Mario Ottiglio, Director, Public Affairs, Communications and Global Health Policy, IFPMA Thank you for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. IFPMA welcomes continued efforts to...
Read moreItem 15.1 Antimicrobial resistance Delivered by Nina Grundmann, Policy Analyst, Global Health Policy, IFPMA Thank you for the opportunity to contribute to this important discussion. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the world. IFPMA commends WHO for its efforts to generate a Global Action Plan to...
Read moreItem 17.3 Substandard/spurious/falsely-labelled/falsified/counterfeit medical products Delivered by Cyntia Genolet, Policy Analyst, Regulatory & Health Policy Thank you on behalf of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) for the opportunity to contribute to this important discussion today. IFPMA represents leading research-based pharmaceutical companies as well as national and regional industry associations across the...
Read moreIFPMA and its members express our deepest sympathy to people affected by the devastating earthquake that struck Nepal on 25 April 2015. The global research-based pharmaceutical industry represented by the IFPMA is providing significant funds to relief organisations following the major earthquake. The total cash value of the first emergency responses provided so far by...
Read moreProfessionnels des affaires règlementaires, représentants des autorités de réglementation ou de la société civile et autres professionnels impliqués dans la lutte contre les faux médicaments se réunissent à Dakar dans le cadre d’un séminaire pour discuter d’ une approche intégrée contre les faux médicaments. Dakar (Sénégal) – Un séminaire sur la problématique des faux médicaments...
Read more• Report produced by leading R&D based pharmaceutical companies calls for a coherent, comprehensive and integrated approach at global and national levels to minimize growth of resistance to antibiotics. Preventing resistance requires a joint approach from healthcare professionals, pharmaceutical industry, policy makers and individual citizens to work together to promote appropriate antibiotic use. • Report...
Read moreClick here to listen to the full interview
Read moreIFPMA firmly supports the efforts of governments and civil society to increase access to medicines in developing countries, particularly in LDCs. Ensuring the availability, accessibility, and affordability of medicines is complex, and must be viewed within the overall context of universal health coverage. The vast majority of essential medicines are not protected by intellectual property...
Read morePlus de 150 experts réglementaires de quelques 40 différents pays se réunissent à Dakar, Sénégal. Ils représentent, entre autres, des agences gouvernementales, des organisations multilatérales, l’industrie pharmaceutique, et la société civile pour discuter des moyens permettant d’accélérer la disponibilité des médicaments et vaccins pour les patients en Afrique. Dakar, 27-28 avril 2015 – DIA (Développer,...
Read more